---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-001339"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2023-03-02T23:59:59+00:00"
generated_at: "2026-06-18T14:54:08.303221+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arbutus reports FY2022 net loss $69.5M, cash runway into Q4 2024; pipeline milestones set for 2023

## Summary
- Net loss $69.5M ($0.46/share) vs $88.4M in 2021; revenue $39M up from $11M on Qilu license.
- Cash $184.3M; expects net cash burn $95-100M in 2023, runway into Q4 2024.
- AB-729 Phase 2a data with IFN expected H1 2023; trial with VTP-300 + nivolumab amended.
- Phase 1 trials for oral PD-L1 AB-101 and RNA destabilizer AB-161 to start H1 2023; data H2 2023.
- AB-343 (M pro inhibitor) Phase 1 expected H2 2023; discontinued AB-729+vebicorvir trial.

## SEC filing metadata
- accession: 0001171843-23-001339
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2023-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184323001339/0001171843-23-001339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184323001339/f8k_030223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-001339
- JSON: https://secwatch.observer/filing/0001171843-23-001339.json
- Plain text: https://secwatch.observer/filing/0001171843-23-001339.txt

## Key facts
- Earnings Releases
  Arbutus Biopharma Corp reported financial results for the fourth quarter and year ended December 31, 2022.
  - Period: the fourth quarter and year ended December 31, 2022
  - Result: reported results
  source text: On March 2, 2023, Arbutus Biopharma Corporation (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022 and certain other information.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184323001339/0001171843-23-001339-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.